tbuckley/cabot-search huggingface dataset:
AB0568 MILD ELEVATION OF CREATINE KINASE LEVELS BY JAK INHIBITORS INDEPENDENTLY OF CHANGE IN MUSCLE MASS: ANALYSIS OF DATA FROM A MULTICENTER, PROSPECTIVE, OBSERVATIONAL STUDY
Authors: M. Tada, Y. Matsumoto, T. Koike, K. Mamoto, T. Nakamura, S. Anno, T. Iida, H. Goto, N. Hidaka
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> We reported that creatine kinase (CK) levels were increased by JAK inhibitors in rheumatoid arthritis (RA) patients in a retrospective study <sup>1</sup>. There are no reports of whether JAK selectivity makes a difference in CK elevation. The relationship between CK elevation by JAK inhibitors and changes in muscle mass is also unclear. <h3>Objectives:</h3> Whether JAK inhibitors increased CK levels was investigated in a multicenter, prospective, observational study. The relationship between CK elevation caused by JAK inhibitors and changes in muscle mass was also analyzed. <h3>Methods:</h3> The 0 and 24-week data from the multicenter, prospective, observational study, "Effects of Biologics and JAK Inhibitors on Sarcopenia in RA (PRESENT Study)," were analyzed. In 200 RA patients requiring enhanced therapy, changes in their CK levels and muscle mass were analyzed from the following three perspectives: (1) csDMARDs vs b-/ts-DMARDs; (2) JAK inhibitors vs biologics; and (3) among the five JAK inhibitors. Correlations of changes in CK and muscle mass were evaluated using Spearman's rank correlation coefficient. <h3>Results:</h3> The patients' median age was 70 years, the median duration of disease was 4.5 years, and the mean DAS28-ESR was 4.77. Data for 24 weeks were available for 191 patients. There were no significant differences in CK levels or muscle mass at week 0. (1) The change in the CK level was significantly greater in the b-/ts-DMARDs group than in the csDMARDs group (median 17.0 vs. 9.0 IU/L, p=0.001). (2) The change in CK levels was significantly greater in the JAK inhibitor group than in the biologic group (median 46.0 vs 10.0 IU/L, p&lt;0.001). (3) There was no significant difference in the change in CK levels among the five JAK inhibitor groups (p=0.487) (Figure 1). The change in muscle mass was not significantly different in any comparison (1)-(3). No correlation was found between changes in CK levels by JAK inhibitors and muscle mass (p=0.503) (Figure 2). There were no cases of elevations in CK level of Grade 2 or higher (over 2.5 times the baseline value) at 24 weeks. <h3>Conclusion:</h3> In a multicenter, prospective, observational study, changes in CK levels were significantly greater with JAK inhibitors than with other treatments in RA patients. However, regardless of JAK selectivity, the CK level increase at 24 weeks was mild. The lack of correlation between CK level elevation caused by JAK inhibitors and changes in muscle mass is interesting, and its mechanism remains to be elucidated. <h3>REFERENCES:</h3> [1] Tada M, Okano T, Mamoto K, et al. POS0840 THE DIFFERENCE IN CREATINE KINASE ELEVATION CAUSED BY JAK INHIBITORS AND IL-6 INHIBITORS IN RHEUMATOID ARTHRITIS. 2023; 82:718-. <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB0586 ASSOCIATION BETWEEN RHEUMATOID ARTHRITIS AND CHRONIC DIZZINESS AND RECURRENT FALLS: RESULTS FROM THE KOREAN NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY
Authors: H. Jeong, C. H. Jeon, E. J. Park, Y. S. Chang
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease that leads to various systemic complications. <h3>Objectives:</h3> This study aims to evaluate the association between RA and chronic dizziness and recurrent falls in Korean adult population. <h3>Methods:</h3> Data from 4,754 (weighted n = 17,694,932) individuals aged 40 years or older in the 2019-2020 Korean National Health and Nutrition Examination Survey (KNHANES) was used for analysis. Questionnaire including information on chronic dizziness, recurrent falls, demographic variables, and laboratory test data were evaluated. Potential factors associated with chronic dizziness and recurrent falls were analyzed. <h3>Results:</h3> The mean age was 56.7 years. The weighted prevalence of RA was 1.9%. Chronic dizziness was reported by 3.5% of participants, and 0.5% reported recurrent falls lasting more than 3 months. In multivariable analysis, females (Odds ratio (OR): 2.65, 95% CI 1.60-4.39, p &lt; 0.001), body mass index less than 25 (OR 1.61, 95% CI 1.08-2.38, p = 0.020), hearing impairment (OR 2.16, 95% CI 1.50-3.13, p &lt; 0.001), stroke (OR 2.19, 95% CI 1.13-4.27, p = 0.022), stress (OR 2.67, 95% CI 1.61-4.42, p &lt; 0.001), and RA (OR 2.65, 95% CI 1.10-6.34, p = 0.030) were associated with an increased risk of chronic dizziness. Additionally, females (OR 5.72, 95% CI 1.66-19.68, p = 0.006), hearing impairment (OR 3.03, 95% CI 1.14-8.07, p = 0.028), and RA (OR 8.29, 95% CI 2.79-24.67, p &lt; 0.001) were associated with the increased risk of recurrent falls in the multivariable analysis. <h3>Conclusion:</h3> RA was found to be independently associated with an increased risk of chronic dizziness and recurrent falls. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB0607 SOLUBLE INTERLEUKIN-33 RECEPTOR (sST-2) - A NOVEL MARKER FOR ASSESSING CARDIOVASCULAR RISK IN RHEUMATOID ARTHRITIS
Authors: S. Patschan, I. Claus, M. Hoffmeister, C. Remus, O. Ritter, D. Patschan
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Rheumatoid arthritis endagers affected patients due to chronic inflammation in the synovial joints and increased cardiovascular morbidity. The latter is a result of ongoing inflammation as well as the potentially harmful effects of medications used to manage the disease, such as NSAIDs. Consequently, the assessment of cardiovascular risk (CVR) based on the 2018 ESC criteria may not accurately reflect the true CVR in RA individuals. Soluble IL-33 receptor (sST-2) has shown promise as a predictor of outcomes in acute kidney injury and other conditions. <h3>Objectives:</h3> In this study, we aimed to investigate the role of sST-2 in assessing disease activity and cardiovascular risk in rheumatoid arthritis. <h3>Methods:</h3> Observational, cross-sectional study including RA patients with or without DMARD therapy. RA disease activity and CVR were evaluated according to established criteria. Serum sST-2 was measured by ELISA. <h3>Results:</h3> A total of 129 patients were included in the study. Serum sST-2 did not correlate with, nor was it associated with any variable of RA disease activity (such as VAS, HFQ, DAS 28, or C-reactive protein). Aberrant sST-2 levels were, nonetheless, detected in various surrogate markers of increased cardiovascular risk (CVR), revealing numerous (n=17) significant findings in patients with rheumatoid arthritis (RA) (e.g. gender, age, distress, lack of regular exercise, familiy history of coronary artey disease, diabetes mellitus, framingham score and others.). <h3>Conclusion:</h3> Our findings reveal a novel role for sST-2 in predicting CVR in RA. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
OP0240 HIGH PLASMA C5a AND C5b-9 LEVELS DURING QUIESCENT PHASES ARE ASSOCIATED WITH SEVERE ANTIPHOSPHOLIPID SYNDROME SUBSETS
Authors: A. Ruffatti, A. Hoxha, M. Tonello, A. Calligaro, T. Del Ross, M. Favaro, M. Zen, M. Lovisotto, A. Doria, P. Simioni
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Complement activation has recently emerged, implicated in the pathogenesis of antiphospholipid syndrome (APS)-related clinical events. High plasma C5a and C5b-9 levels are considered a sign of complement activation. <h3>Objectives:</h3> To evaluate the association of C5a and C5b-9 plasma levels with different clinical and laboratory APS subsets. <h3>Methods:</h3> We conducted a monocentric exploratory cross-sectional study. Plasmas of 62 quiescent APS patients [40 with thrombosis responsive to vitamin K antagonists (VKA) therapy (TAPS), 13 with refractory to VKA recurrent thrombosis (RAPS), 9 with CAPS], 13 active APS(2 TAPS, 7 RAPS, and 4 CAPS), and 30 sex and age-matched healthy controls (HC) were recruited. Plasma concentrations of C5a and C5b-9 were assessed using commercial ELISA assays. <h3>Results:</h3> The C5b-9 levels in quiescent CAPS were significantly higher than in TAPS [median, 330.2 ng/mL (IQR, 86.6); vs 189.7 ng/mL (IQR, 138.9) and in HC [median, 330.2 ng/mL (IQR, 86.6) vs 120.9 ng/mL (IQR, 83.7)]. Similarly, the C5a levels were significantly higher in CAPS than in TAPS [median, 27.6 ng/mL (IQR, 58.4) vs. 8.9 ng/mL (IQR, 8.3) and the HC [median, 27.6 ng/mL (IQR, 58.4) vs. 4.9 ng/mL (IQR, 4.9)]. Moreover, both C5a and/or C5b-9 were significantly higher in RAPS than in TAPS [median 15.6 ng/mL (IQR, 51.8) vs. 11.6 ng/mL (IQR, 9.3) and median 814.6 ng/mL (IQR, 2808.4) vs. 309.6 (291.7)]. In addition, C5a and/or C5b-9 significantly prevailed in the patients with active APS vs. Quiescent APS [median 41.2 ng/mL (IQR, 67.3) vs. 14.3 ng/mL (IQR, 8.3) and median 1691.0 ng/mL (IQR,1788.3) vs. 448.9 ng/mL (IQR, 463.6)] as well as in the small-vessel thrombosis (p=0.0088), just as C5b-9 did in the triple antiphospholipid antibody-positive patients (p=0.0248). The ROC curve showed that the best cut-offs for C5a and C5b-9 levels had a higher sensitivity, specificity, and likelihood ratio in the CAPS and RAPS groups than in the TAPS subset. <h3>Conclusion:</h3> High plasma C5b-9 and C5a levels during quiescent phases identify APS patients with more severe disease who may develop recurrent thrombosis and benefit from complement inhibition treatment during an acute disease phase. <h3>REFERENCES:</h3> [1] Chaturvedi S, Braunstein EM, Yuan X, Yu J, Alexander A, Chen H, Gavriilaki E, Alluri R, Streiff MB, Petri M, Crowther MA, McCrae KR, Brodsky RA. Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood. 2020 Jan 23;135(4):239-251. doi:10.1182/blood.2019003863. <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
OP0214 ASSOCIATIONS OF REMNANT CHOLESTEROL WITH ALL-CAUSE AND CAUSE-SPECIFIC THROMBOTIC RISK IN INDIVIDUALS WITH ANTIPHOSPHOLIPID SYNDROME
Authors: J. Zhao, B. Cai, Y. Zhou, X. Tian, M. Li, X. Zeng
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Antiphospholipid syndrome (APS) is notably linked to thrombotic events, particularly cardiovascular disease (CVD). The role of remnant cholesterol (RC) in predicting CVD risk is established, yet its relationship with thrombotic risk in APS patients remains to be elucidated. <h3>Objectives:</h3> This study aims to assess the association between RC and thrombosis in patients with APS. <h3>Methods:</h3> A prospective analysis was conducted based on a cohort of APS patients who met the 2006 Sydney revised classification criteria. The thrombotic risk associated with varying RC levels was evaluated using Kaplan-Meier survival analysis and Cox proportional hazards regression. Additionally, mendelian randomization (MR) was applied to determine the causal link between RC and thrombotic events. <h3>Results:</h3> A total of 325 patients with APS were enrolled in this study. After a median follow-up of 31 months, 83 patients experienced thrombotic events, including 38 venous, 27 arterial, and 31 microvascular thromboses. Compared with low RC levels, individuals with RC &gt;0.65 mmol/L had multivariate-adjusted hazard ratio (HR) and 95% confidence interval (CI) for all-cause, venous, arterial, and microvascular thrombosis were 2.86 (1.61, 5.10), 2.96 (1.14, 7.71), 3.00 (1.11, 8.12), and 2.84 (1.12, 7.20), respectively, all with P-trend values &lt;0.05. Elevated RC remained a significant thrombotic risk factor even in individuals with normal conventional lipid indices. MR analysis revealed a significant causal association between RC and arterial thrombosis, but not venous thrombosis. <h3>Conclusion:</h3> Our findings indicate that high RC levels are associated with a nearly threefold increase in thrombotic risk, encompassing arterial, venous, and microvascular events, in APS patients. This underscores the importance of monitoring and managing RC levels in this patient population. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> The authors are indebted to all participants in APS cohorts from PUMCH. <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB0936 THE INCIDENCE OF FUNGAL INFECTIONS IN PATIENTS WITH SPONDYLOARTHRITIS UNDER BIOTHERAPY IN THE MOROCCAN REGISTRY OF BIOTHERAPY: 3-YEAR FOLLOW-UP
Authors: S. Bourjila, S. Rostom, A. Souissi, B. Amine, I. EL Binoune, I. Hmamouchi, R. Abouqal, L. Achemlal, F. Allali, I. El Bouchti, A. El Maghraoui, I. El Ghozlani, H. Hassikou, T. Harzy, L. Ichchou, O. Mkinsi, R. Niamane, R. Bahiri
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Immunomodulating biological agents increase the risk of fungal infections in patients with chronic inflammatory rheumatism, however, they have been more frequently described in rheumatoid arthritis. <h3>Objectives:</h3> To determine the incidence of fungal infections in patients with spondyloarthritis on biotherapy in the Moroccan registry of biotherapy (RBSMR) at 3-year follow-up and to identify factors associated with the risk of infection in these patients. <h3>Methods:</h3> This was a prospective study, with a three-year follow-up, which included 194 spondyloarthritis patients treated with biologics. Patients' sociodemographic clinical and paraclinical data were collected. The type of biotherapy used and episodes of fungal infections before and during treatment were reported. Any resulting changes in treatment were reported. Also reported were the frequency of use of corticosteroids and NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), disease activity, and various comorbidities before and at the time of fungal infection during the 3 years of follow-up. Regarding fungal infection, the germ and location were specified. <h3>Results:</h3> The mean age of patients was 43.23±13.68 years, with a male predominance (63.4%). Seven spondyloarthritis patients out of 194 (3.6%) had a fungal infection, including 4 men and 3 women. The mean age was 44±17.23 years, with a mean disease duration of evolution of 11 years. All 7 patients had comorbidities before and during the fungal infection. At the time of the fungal infection, only 1 patient was on corticosteroids, and no use of CsDMARDS (Conventional synthetic Disease-Modifying Antirheumatic Drugs) was noted at the time of infection. Six patients were on TNF alpha inhibitors at the time of infection (5 ADALIMUMAB, 1 ETANERCEPT), and 1 patient on SECUKINUMAB. In terms of treatment, a transient discontinuation of biologics was recommended, but no switch was observed in any of the 7 patients. Patients were active both before and after the infection. No cases of systemic fungal infection were noted. In the 8 cases of fungal infections, there were 7 cases of phanereal involvement, including one with TRICHOPHYTON RUBRUM and 1 case of vaginal candidiasis. <h3>Conclusion:</h3> The incidence of fungal infections in patients with spondyloarthritis is low, and remains similar to data in the literature. It seems to be related to disease activity and type of biologics. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
POS0853 ELDERLY SYSTEMIC SCLEROSIS. CLINICAL PRESENTATION AND OUTCOME
Authors: M. Retuerto-Guerrero, C. Sieiro Santos, C. Moriano, I. González, I. González Fernández, C. Díez, C. Álvarez Castro, P. Pérez-García, J. Ordas Martínez, P. Baenas González, E. Diez Álvarez
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Immunosenescence is the process by which the immune system deteriorates over time, and is associated with an increased frequency of infections, cancer and an increase in the development of autoimmune diseases. Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis, vascular dysfunction and the presence of several autoantibodies. Age at onset may modulate the clinical characteristics and associated poor prognosis in SSc. <h3>Objectives:</h3> We aim to evaluated if age at SSc onset modulates the clinical phenotype and outcome of our cohort. <h3>Methods:</h3> An observational retrospective monocenter study. We included 133 patients with diagnosis of SSc according to modified ACR-EULAR 2013 criteria. Based on median age at disease onset of our cohort, 59.7 (51-69.3) year, the patients ≥70 years formed the "late onset group". We compared clinical manifestations, antibody status, treatment, malignancy and death rates. Continuous variables were compared by Student's or Mann Whitney's T test, and categorical variables by Chi<sup>2</sup> test or Fisher's exact test. Survival curves were calculated using the Kaplan-Meier method, and the log rank ratio was used to identify differences. <h3>Results:</h3> The late-onset group incluyed 31 patient, 58% female, mean age at SSc onset 76.27± 4.5 years. Clinical, immunological, treatment and outcome data are summarized in Table 1. "Late-onset" group was more frequently anti-TIF1-γ positive and presented higher rates of cardiac involment and PAH. Digital ulcers were more common in "standar-onset" group, but they showed torpid evolution in "late-onset" group. Immunosuppressive drugs were prescribed more frequently in "standar-onset" group. Malignancy rates was similar in both groups. All-cause and SSc-related mortality were higher in "late-onset" group. Time to PAH, ILD and death was significantly different between groups (log rank test p &lt; 0,001, Figure 1). Time to malignancy was similar between groups. <h3>Conclusion:</h3> Our study suggests that elderly onset SSc patients presents more severe manifestations and at an earlier stage, despite this, they receive less targeted treatment. <b>REFERENCES: NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB1156 IMMUNOGLOBULINS G FROM SYSTEMIC SCLEROSIS PATIENTS MODIFY THE PROTEOME OF ENDOTHELIAL CELLS DEPENDING ON ANTINUCLEAR ANTIBODIES SPECIFICITY
Authors: A. Chepy, S. Viver, A. Elhannani, F. Bray, C. Chauvet, L. Guilbert, L. Bourel, C. Rolando, E. Hachulla, S. Dubucquoi, D. Launay, V. Sobanski
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Systemic sclerosis (SSc) is a heterogeneous connective tissue disease characterized by autoimmunity, vasculopathy and excessive fibrosis. Functional antibodies such as angiotensin II type 1 receptor and endothelin-1 type A receptor have been described in SSc and might be implicated in vasculopathy, in which endothelial cells (EC) are key players. Antinuclear antibodies (ANA) are strong diagnostic and prognosis biomarkers but their pathogenicity in vasculopathy remains unclear. <h3>Objectives:</h3> To explore the effect of purified IgG from SSc patients on the proteome of EC and analyse the influence of ANA. <h3>Methods:</h3> Human umbilical vein endothelial cells (HUVEC) were cultured in presence of purified IgG from: 10 diffuse cutaneous SSc (dcSSc) anti-topoisomerase-I positive patients (dcSSc ATA+), 10 limited cutaneous SSc anticentromere positive patients (lcSSc ACA+), 10 dcSSc anti-RNA polymerase III autoantibodies positive patients (dcSSc RNAP+), 10 healthy controls (HC) and 5 patients with systemic lupus erythematosus (SLE). After 24h, the proteome was analysed using Liquid Chromatography with tandem Mass Spectrometry. Proteomic data were visualized by principal component analysis (PCA). Differential analysis and enrichment analysis were performed to compare pattern of protein expression between groups <h3>Results:</h3> Proteomics identified and quantified 2,141 proteins. PCA showed 3 distinct groups of subjects: a first including mostly dcSSc ATA+, a second including mostly lcSSc ACA+ and third groups more heterogeneous including dcSSc RNAP+ patients, SLE patients and HC (<b>Figure 1</b>). The comparison of HUVEC's proteome in the presence of purified IgG from dcSSc ATA+ vs HC and lcSSc ACA+ vs HC revealed 614 and 288 differentially expressed proteins respectively. Proteins overexpressed in dSSc ATA+ group were enriched in macromolecule localization and protein binding and overexpressed proteins in lcSSc ACA+ groups were enriched in RNA and mRNA proteins binding. Eleven proteins were commonly overexpressed in dcSSc ATA+ or lcSSc ACA+. <h3>Conclusion:</h3> Using a proteomic approach, we identified that IgG from SSc modified EC proteome which appeared explained by ANA status. In particular, IgG from both ATA+ et ACA+ patients induced EC singular and distinct proteomic profiles. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB0048 CHARACTERISTICS OF OCULAR INVOLVEMENT IN BEHÇET DISEASE IN A TUNISIAN PATIENTS COHORT
Authors: B. Mayssa, H. Tounsi, S. Dghais, S. Wafa, R. Amri
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Ocular involvement in Behcet's disease (BD) is common and severe. According to the literature, it occurs in 25% to 80% of cases. <h3>Objectives:</h3> Our study aimed to determine the epidemiological, clinical, therapeutic and prognostic features of ocular involvement in patients with Behçet's disease. <h3>Methods:</h3> A retrospective and descriptive study was conducted within the internal medicine department of Taher Maamouri Hospital, between 2015 and 2023. All patients meeting the new MB classification criteria (International Criteria for Behçet's Disease: ICBD) and having ocular involvement were included. <h3>Results:</h3> In a cohort of 110 patients diagnosed with Behçet's disease, thirty-seven had ocular involvement (33.6%). The male-female ratio was 4,28. The mean age at onset of ocular involvement was 28.14 years. Ocular involvement was inaugural in 24 cases. The mean delay between the onset of ocular involvement and the diagnosis of Behçet's disease was 5.18 months. Ocular involvement was bilateral in 26 cases. Uveitis was the most common ocular manifestation (33 cases), followed by retinal thrombosis in 2 cases, episcleritis in 2 cases and optic neuropathy in one case. The uveitis was anterior in 9 cases (24.3%), intermediate in 1 case (2.7%), posterior in 5 cases (%) and panuveitis in 18 cases (48.6%). Retinal vasculitis was noted in 16 cases. Extra-ocular manifestations included: mucocutaneous involvement in all patients, joint involvement (n=17), neurological involvement (n=7) and vascular involvement (n=6). All patients having an ocular involvement were treated with corticosteroids. Local treatment was prescribed in 27 patients. Immunosuppressive (IS) treatments were used in 22 patients. Cyclophosphamide was the most used as first-line treatment (40%) followed by azathioprine in 5 cases and ciclosporin in one case. One patient was treated with anti-TNF alpha. Ocular complications were noted in 13 patients including synechiae (2 cases; 5.4%), blindness (3 cases; 8.1%) and chorioretinal detachment (1 case; 2.7%). After an average follow-up of 1 year, 21,6% of patients had stable visual acuity while receiving treatment and 13,5% had a significant decrease in visual acuity. <h3>Conclusion:</h3> Early and appropriate management of ocular involvement in Behcet's disease is essential to improve visual prognosis. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>